跳至主要内容
临床试验/NCT04063956
NCT04063956Unknown不适用

The Efficacy of COGnitive tRaining in patiEnts With Amnestic Mild coGnitive impairmENT (COG-REAGENT): a Multi-center Randomized Controlled Trial

Xuanwu Hospital, Beijing2 个研究点 分布在 1 个国家目标入组 260 人开始时间: 2019年11月6日最近更新:
适应症

试验速览

阶段
不适用
入组人数
260
试验地点
2
主要终点
Change in Montreal Cognitive Assessment

研究概览

简要总结

This study evaluates the efficacy and mechanism of internet-based cognitive training in patients with amnestic mild cognitive impairment (aMCI). Half of participants will receive multi-domain adaptive internet-based training program, while the other half will receive a fixed, primary difficulty level task.

详细描述

Background: Alzheimer's disease (AD) is the most common dementia and the major cause for senile dementia. With the increase of life expectancy, AD has become a global problem. However, to date, drug therapies only have modest benefits for patients with AD. Recently, researchers have begun to focus on early intervention of AD at its preclinical stages. Individuals with amnestic mild cognitive impairment (aMCI), often the prodromal stage of AD, report mild short-term memory difficulties but preserved independence in activities of daily living. The aMCI stage is important to slow or even prevent the development of AD. Some previous studies have suggested cognitive training is a potential non-pharmacological intervention for aMCI, however, the results were inconsistent. Thus, investigators will conduct this multi-center randomized controlled trial to explore whether and how cognitive training improves cognitive function in patients with aMCI.

Objectives: The first aim of this multi-center single-blinded, randomized controlled trial is to assess whether internet-based cognitive training improves cognitive abilities in patients with aMCI. Furthermore, the second objective is to evaluate the effect of cognitive training on neural plasticity, including brain activation and white matter integrity, which are assessed by functional and structural MRI.

Patients and Methods: The study will include 260 patients diagnosed with aMCI from eight centers around China. The patients will be randomized to either a cognitive training group or an active-control group. The intervention is 12-week internet-based cognitive training performed for 40 minutes per day, 4 days a week. Within each task, high accuracy (80%) is required to upgrade to the next difficulty level. The active- control group will receive five processing speed and attention tasks, whose duration also total to 40 min each training day. However, these tasks are set to a fixed, primary difficulty level across the study.

Neuropsychological assessments and structural and functional magnetic resonance imaging (MRI) will be performed at the baseline, end of intervention, and 6 months after randomization to measure long-term resilience of the effect.

Relevance: Early intervention of aMCI has the potential to delay or even prevent the development of dementia. Some previous studies have suggested cognitive training is a potential non-pharmacological intervention for aMCI, however, the results were inconsistent. Thus, the proposed study is to determine the efficacy of cognitive training in patients with aMCI. Secondly, using functional and structural MRI, this study is to reveal the potential mechanisms underlying cognitive training.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Investigator, Outcomes Assessor)

入排标准

年龄范围
50 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Literate Han Chinese, 50-85 years of age with a caregiver that accompanies the subject consistently at least 4 days a week;
  • Complaint and/or informant report of a cognitive impairment lasting for at least 3 months;
  • Clinical diagnosis of MCI according to the MCI core clinical criteria of the National Institute on Aging-Alzheimer's Association (NIA-AA) guidelines;
  • A prominent manifestation of memory deficit with or without other cognitive domain impairments;
  • Mini-Mental State Examination (MMSE) score ≥24, and Clinical dementia rating (CDR) = 0.5, and
  • Normal or slightly impaired activities of daily living as defined by a total score of ≤ 1.5 on the three functional CDR domains (home and hobbies, community affairs, and personal care).

排除标准

  • Severe aphasia, physical disabilities, or any other disease that may preclude completion of neuropsychological testing;
  • A medical history of stroke with focal neurological features including hemiparesis, sensory loss, visual field deficits, and evidence of responsible lesions on MRI;
  • Significant white matter lesions (Fazekas score = 3-6);
  • Disorders other than aMCI that may affect cognition;
  • Depression or other psychiatric disorders;
  • Clinically significant gastrointestinal, renal, hepatic, respiratory, infectious, endocrine, or cardiovascular diseases, cancer, alcoholism, drug addiction;
  • Use of medications that may affect cognitive functioning, including tranquilizers, anti-anxiolytics, hypnotics, nootropics, and cholinomimetic agents;
  • Inability to undergo a brain MRI; and
  • Other conditions that in the investigator's opinion might not be suitable for the study.

结局指标

主要结局

Change in Montreal Cognitive Assessment

时间窗: 12 weeks (end of intervention)

Montreal Cognitive Assessment (MoCA) will be used to evaluate the general cognitive function. MoCA ranges from 0 to 30, and higher value represents a better outcome.

次要结局

  • Change in brain volume and white matter integrity(12 weeks (end of intervention), 6 months)
  • Change in Trail Making Test(12 weeks (end of intervention), 6 months)
  • Change in Digit span forward(12 weeks (end of intervention), 6 months)
  • Change in Boston Naming Test(12 weeks (end of intervention), 6 months)
  • Change in Clinical Dementia Rating Scale sum of the boxes(12 weeks (end of intervention), 6 months)
  • Change in memory function(12 weeks (end of intervention), 6 months)
  • Change in Activities of Daily Living(12 weeks (end of intervention), 6 months)
  • Change in Quality of Life-Alzheimer's Disease (QoL-AD) Scale(12 weeks (end of intervention), 6 months)
  • Change in Mini-mental State Examination(12 weeks (end of intervention), 6 months)
  • Change in Montreal Cognitive Assessment(6 months)
  • Change in Digit span backward(12 weeks (end of intervention), 6 months)
  • Change in Alzheimer's Disease Assessment Scale cognitive subscale (ADAS-cog, 11-items version).(12 weeks (end of intervention), 6 months)
  • Change in brain connectivity(12 weeks (end of intervention), 6 months)
  • Change in Cookie Theft picture description task(12 weeks (end of intervention), 6 months)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验